Issues with Medication for Cardiovascular Disease Patients Admitted to the Medical Ward
DOI:
https://doi.org/10.56801/MME1205Keywords:
Cardiovascular Diseases (CVD), Drug Therapy Problems (DTPs), Medication Management in Hospitalized Patients.Abstract
Background: Cardiovascular diseases (CVD) remain a significant public health concern globally, with medications playing a critical role in their management. However, drug therapy problems (DTPs) pose a substantial challenge, leading to adverse patient outcomes, increased healthcare costs, and preventable hospitalizations. Limited studies have comprehensively explored DTPs among hospitalized CVD patients, emphasizing the need for further research.
Methods: A prospective observational study was conducted on 242 CVD patients admitted to a medical ward . Data were collected through patient interviews and review of medical and laboratory records. DTPs were identified and classified using Cipolle’s framework. Logistic regression analysis was employed to identify predictors of DTPs, with a p-value < 0.05 considered statistically significant.
Results: A total of 177 DTPs were identified, affecting 52.7% of patients, with a mean of 1.4 DTPs per patient. The most common DTPs were the need for additional drug therapy (32.4%), ineffective drug therapy (14%), and unnecessary drug therapy (13.1%). Frequently implicated medications included beta blockers (19.4%), antithrombotics (14.4%), and statins (13%). Older age (AOR: 3.97; 95% CI: 1.68–9.36) and polypharmacy (AOR: 2.68; 95% CI: 1.47–5.11) were significant predictors of DTPs.
Conclusion: More than half of the hospitalized CVD patients experienced DTPs, predominantly due to suboptimal medication management. Older age and polypharmacy were identified as significant contributors to DTPs. Interventions such as medication reconciliation and adherence to standardized clinical guidelines are essential to reduce DTPs, improve patient outcomes, and optimize CVD management.
References
Roth GA, Mensah GA, Johnson CO, Addolorato G, Ammirati E, Baddour LM, et al. Global burden of cardiovascular diseases and risk factors, 1990–2019: update from the GBD 2019 study. J Am Coll Cardiol. 2020;76(25):2982–3021. doi: 10.1016/j.jacc.2020.11.010.
Deaton C, Froelicher ES, Wu LH, Ho C, Shishani K, Jaarsma T. The global burden of cardiovascular disease. Eur J Cardiovasc Nurs. 2011;10 Suppl 2:S5–13. doi: 10.1016/S1474-5151(11)00111-3.
Benjamin EJ, Virani SS, Callaway CW, Chamberlain AM, Chang AR, Cheng S, et al. Heart disease and stroke statistics-2018 update: a report from the American Heart Association. Circulation. 2018;137(12):e67. doi: 10.1161/CIR.0000000000000558.
Yuyun MF, Sliwa K, Kengne AP, Mocumbi AO, Bukhman G. Cardiovascular diseases in Sub-saharan Africa compared to high-income countries: an epidemiological perspective. Glob Heart. 2020;15(1):15. doi: 10.5334/gh.403.
Keates AK, Mocumbi AO, Ntsekhe M, Sliwa K, Stewart S. Cardiovascular disease in Africa: epidemiological profile and challenges. Nat Rev Cardiol. 2017;14(5):273–93. doi: 10.1038/nrcardio.2017.19.
Angaw DA, Ali R, Tadele A, Shumet S. The prevalence of cardiovascular disease in Ethiopia: a systematic review and meta-analysis of institutional and community-based studies. BMC Cardiovasc Disord. 2021;21(1):37. doi: 10.1186/s12872-020-01828-z.
Ali S, Misganaw A, Worku A, Destaw Z, Negash L, Bekele A, et al. The burden of cardiovascular diseases in Ethiopia from 1990 to 2017: evidence from the global burden of disease study. Int Health . 2021;13(4):318–26.
Wieser M, Rhyner D, Martinelli M, Suter T, Schnegg B, Bosch C, et al. [Pharmacological therapy of heart failure with reduced ejection fraction] Ther Umsch. 2018;75(3):180–6. doi: 10.1024/0040-5930/a000986.
Milner J, Cunha A, Gamboa-Cruz C, Reis J, Campos M, António N. Recent major advances in cardiovascular pharmacotherapy. Eur J Clin Pharmacol. 2018;74(7):853–62. doi: 10.1007/s00228-018-2453-1.
Niquille A, Bugnon O. Relationship between drug-related problems and health outcomes: a cross-sectional study among cardiovascular patients. Pharm World Sci. 2010;32(4):512–9. doi: 10.1007/s11096-010-9401-1.
Gelchu T, Abdela J. Drug therapy problems among patients with cardiovascular disease admitted to the medical ward and had a follow-up at the ambulatory clinic of Hiwot Fana Specialized University Hospital: the case of a tertiary hospital in eastern Ethiopia. SAGE Open Med. 2019;7:2050312119860401. doi: 10.1177/2050312119860401.
Chang HY, Wang CC, Wei J, Chang CY, Chuang YC, Huang CL, et al. Gap between guidelines and clinical practice in heart failure with reduced ejection fraction: results from TSOC-HFrEF registry. J Chin Med Assoc. 2017;80(12):750–7. doi: 10.1016/j.jcma.2017.04.011.
Abolbashari M, Macaulay TE, Whayne TF, Mukherjee D, Saha S. Polypharmacy in cardiovascular medicine: problems and promises! Cardiovasc Hematol Agents Med Chem. 2017;15(1):31–9. doi: 10.2174/1871525715666170529093442.
Michaels AD, Spinler SA, Leeper B, Ohman EM, Alexander KP, Newby LK, et al. Medication errors in acute cardiovascular and stroke patients: a scientific statement from the American Heart Association. Circulation. 2010;121(14):1664–82. doi: 10.1161/CIR.0b013e3181d4b43e.
Strand LM, Cipolle RJ, Morley PC. Pharmaceutical care practice. New York: McGraw-Hill; 2012.
Dahal P, Venkataraman R, Fuloria PC. Assessment of clinical pharmacist intervention in tertiary care teaching hospital of Southern India. Asian J Pharm Clin Res. 2013;6(2):258–61.
Basger BJ, Moles RJ, Chen TF. Development of an aggregated system for classifying causes of drug-related problems. Ann Pharmacother. 2015;49(4):405–18. doi: 10.1177/1060028014568008.
Gustafsson M, Sjölander M, Pfister B, Jonsson J, Schneede J, Lövheim H. Drug-related hospital admissions among old people with dementia. Eur J Clin Pharmacol. 2016;72:1143–53. doi: 10.1007/s00228-016-2084-3.
Mohammed MA, Moles RJ, Chen TF. Medication-related burden and patients’ lived experience with medicine: a systematic review and metasynthesis of qualitative studies. BMJ Open. 2016;6(2):e010035. doi: 10.1136/bmjopen-2015-010035.
Robertson JJ, Long B. Suffering in silence: medical error and its impact on health care providers. J Emerg Med. 2018;54(4):402–9. doi: 10.1016/j.jemermed.2017.12.001.
Elliott RA, Camacho E, Jankovic D, Sculpher MJ, Faria R. Economic analysis of the prevalence and clinical and economic burden of medication error in England. BMJ Qual Saf. 2021;30(2):96–105. doi: 10.1136/bmjqs-2019-010206.
Rodziewicz TL, Houseman B, Hipskind JE. Medical error reduction and prevention. Treasure Island (FL): StatPearls Publishing; 2022.
Qamariat H. Rational and irrational drug use: factors, impacts and strategies to combat irrational drug use: a narrative review. Int J Pharm Sci Clin Pharm. 2021;2(1):6–17.
Donaldson LJ, Kelley ET, Dhingra-Kumar N, Kieny M-P, Sheikh A. Medication without harm: WHO’s third global patient safety challenge. Lancet. 2017;389(10080):1680–1. doi: 10.1016/S0140-6736(17)31047-4.
Dalton K, Byrne S. Role of the pharmacist in reducing healthcare costs: current insights. Integr Pharm Res Pract. 2017;6:37–46. doi: 10.2147/IPRP.S108047.
Howard R, Avery A, Bissell P. Causes of preventable drug-related hospital admissions: a qualitative study. Qual Saf Health Care. 2008;17(2):109–16. doi: 10.1136/qshc.2007.022681.
Fentie Wendie T, Tarekegn Angamo M. Drug-therapy problems and predictors among hospitalized heart-failure patients: a prospective observational study. Drug Healthc Patient Saf. 2020;12:281–91. doi: 10.2147/DHPS.S268923.
Urbina O, Ferrández O, Luque S, Grau S, Mojal S, Pellicer R, et al. Patient risk factors for developing a drug-related problem in a cardiology ward. Ther Clin Risk Manag. 2015;11:9–15. doi: 10.2147/TCRM.S71749.
Georgiev KD, Hvarchanova N, Georgieva M, Kanazirev B. The role of the clinical pharmacist in the prevention of potential drug interactions in geriatric heart failure patients. Int J Clin Pharm. 2019;41(6):1555–61. doi: 10.1007/s11096-019-00918-z.
Charan J, Biswas T. How to calculate sample size for different study designs in medical research? Indian J Psychol Med. 2013;35(2):121–6. doi: 10.4103/0253-7176.116232.
Niriayo YL, Ibrahim S, Kassa TD, Asgedom SW, Atey TM, Gidey K, et al. Practice and predictors of self-care behaviors among ambulatory patients with hypertension in Ethiopia. PLoS One. 2019;14(6):e0218947. doi: 10.1371/journal.pone.0218947.
Niriayo YL, Kumela K, Kassa TD, Angamo MT. Drug therapy problems and contributing factors in the management of heart failure patients in Jimma University Specialized Hospital, Southwest Ethiopia. PLoS One. 2018;13(10):e0206120. doi: 10.1371/journal.pone.0206120.
James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, Handler J, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8) JAMA. 2014;311(5):507–20. doi: 10.1001/jama.2013.284427.
Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE, Colvin MM, et al. 2017 ACC/AHA/HFSA focused update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice guidelines and the Heart Failure Society of America. J Am Coll Cardiol. 2017;70(6):776–803. doi: 10.1016/j.jacc.2017.04.025.
Arslan F, Voskuil MJNHJ. The management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: early invasive strategy for all? Neth Heart J. 2017;25(3):170–2.
Amsterdam EA, Wenger NK, Brindis RG, Casey DE, Ganiats TG, Holmes DR, et al. 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes. Circulation. 2014;29:CIR. 0000000000000134.
Ibanez B, James S, Agewall S, Antunes MJ, Bucciarelli-Ducci C, Bueno H, et al. 2017 ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: the task force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2018;39(2):119–77.
O’gara PT, Kushner FG, Ascheim DD, Casey DE, Chung MK, De Lemos JA, et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2013;127(4):529–55. doi: 10.1161/CIR.0b013e3182742c84.
Kernan WNOB, Black HR, Bravata DM, Chimowitz MI, Ezekowitz MDFM, Fisher M, Furie KL, Heck DV, Johnston SC, Kasner SE, Kittner SJ, Mitchell PH, Rich MW, Richardson D, Schwamm LH. Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Am Heart Assoc. 2014;45:1524–4628. doi: 10.1161/STR.0000000000000024.
January CTWL, Alpert JS, Calkins H, Cigarroa JE, Cleveland JC, Jr, Ellinor CJ, Ezekowitz PT, Field MD, Murray ME, Sacco KT, Stevenson RL, Tchou WG, Tracy PJ, Yancy CM. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 2014;64(21):2. doi: 10.1016/j.jacc.2014.03.022.
Vahanian A, Alfieri O, Andreotti F, Antunes MJ, Barón-Esquivias G, Baumgartner H, Borger MA, Carrel TP, De Bonis M, Evangelista A, Falk V, Lung B, Lancellotti P, Pierard L, Price S, et al. Guidelines on the management of valvular heart disease (version 2012): the joint task force on the management of valvular heart disease of the European Society of Cardiology (ESC) and the European Association for Cardio-thoracic surgery (EACTS) Eur Heart J. 2012;28:46. doi: 10.1093/ejcts/ezs455.
Al Hamid A, Aslanpour Z, Aljadhey H, Ghaleb M. Hospitalisation resulting from medicine-related problems in adult patients with cardiovascular diseases and diabetes in the United Kingdom and Saudi Arabia. Int J Environ Res Public Health. 2016;13(5):479. doi: 10.3390/ijerph13050479.
Sefera B, Getachew M, Babu Y, Bekele F, Fanta K. Drug-related problems and its predictors among hospitalized heart failure patients at Jimma Medical Center, South West Ethiopia: prospective interventional study. BMC Cardiovasc Disord. 2022;22(1):418. doi: 10.1186/s12872-022-02859-4.
Peltzer K. Health beliefs and prescription medication compliance among diagnosed hypertension clinic attenders in a rural South African hospital. Curationis. 2004;27(3):15–23. doi: 10.4102/curationis.v27i3.994.
Liwa AC, Smart LR, Frumkin A, Epstein H-AB, Fitzgerald DW, Peck RN. Traditional herbal medicine use among hypertensive patients in sub-saharan Africa: a systematic review. Curr Hypertens Rep. 2014;16(6):437. doi: 10.1007/s11906-014-0437-9.
Asfaw Erku D, Basazn Mekuria A. Prevalence and correlates of complementary and alternative medicine use among hypertensive patients in Gondar town, Ethiopia. Evid Based Complement Alternat Med. 2016;2016:6987636. doi: 10.1155/2016/6987636.
Gökçekuş L, Mestrovic A, Basgut B. Pharmacist intervention in drug-related problems for patients with cardiovascular diseases in selected community pharmacies in Northern Cyprus. Trop J Pharm Res. 2016;15(10):2275–81. doi: 10.4314/tjpr.v15i10.29.
Byrne RA, Rossello X, Coughlan JJ, Barbato E, Berry C, Chieffo A, et al. 2023 ESC guidelines for the management of acute coronary syndromes: developed by the task force on the management of acute coronary syndromes of the European Society of Cardiology (ESC) Eur Heart J. 2023;44(38):3720–826. doi: 10.1093/eurheartj/ehad191.
McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, et al. 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42(36):3599–726. doi: 10.1093/eurheartj/ehab368.
Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, et al. 2022 AHA/ACC/HFSA Guideline for the management of Heart failure: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice guidelines. Circulation. 2022;145(18):e895–e1032. doi: 10.1161/CIR.0000000000001063.
Assefa YA, Kedir A, Kahaliw W. Survey on polypharmacy and drug-drug interactions among Elderly people with Cardiovascular diseases at Yekatit 12 Hospital, Addis Ababa, Ethiopia. Integr Pharm Res Pract. 2020;9:1–9. doi: 10.2147/IPRP.S231286.
Koh Y, Kutty FBM, Li SC. Drug-related problems in hospitalized patients on polypharmacy: the influence of age and gender. Ther Clin Risk Manag. 2005;1(1):39–48. doi: 10.2147/tcrm.1.1.39.53597.
Maher RL, Hanlon J, Hajjar ER. Clinical consequences of polypharmacy in elderly. Exp Opin Drug Saf. 2014;13(1):57–65. doi: 10.1517/14740338.2013.827660.
Orehovački H, Brajković A, Bićanić LA, Mucalo I. Polypharmacy-is there a cure for drug therapy problems? Croat Med J. 2023;64(4):295. doi: 10.3325/cmj.2023.64.295.
Greeshma M, Lincy S, Maheswari E, Tharanath S, Viswam S. Identification of drug related problems by clinical pharmacist in prescriptions with polypharmacy: a prospective interventional study. J Young Pharmacists. 2018;10(4):460. doi: 10.5530/jyp.2018.10.100.
Kurczewska-Michalak M, Lewek P, Jankowska-Polańska B, Giardini A, Granata N, Maffoni M, et al. Polypharmacy management in the older adults: a scoping review of available interventions. Front Pharmacol. 2021;12:734045. doi: 10.3389/fphar.2021.734045.
Hanlon JT, Schmader KE, Semla TP. Update of studies on drug-related problems in older adults. J Am Geriatr Soc. 2013;61(8):1365. doi: 10.1111/jgs.12354.
Plácido AI, Herdeiro MT, Morgado M, Figueiras A, Roque F. Drug-related problems in home-dwelling older adults: a systematic review. Clin Ther. 2020;42(4):559–72. doi: 10.1016/j.clinthera.2020.02.005.
Puumalainen E, Airaksinen M, Jalava SE, Chen TF, Dimitrow M. Comparison of drug-related problem risk assessment tools for older adults: a systematic review. Eur J Clin Pharmacol. 2020;76:337–48. doi: 10.1007/s00228-019-02796-w.
Silva C, Ramalho C, Luz I, Monteiro J, Fresco P. Drug-related problems in institutionalized, polymedicated elderly patients: opportunities for pharmacist intervention. Int J Clin Pharm. 2015;37:327–34. doi: 10.1007/s11096-014-0063-2.
Pfister B, Jonsson J, Gustafsson M. Drug-related problems and medication reviews among old people with dementia. BMC Pharmacol Toxicol. 2017;18:1–11. doi: 10.1186/s40360-017-0157-2.
Parsons C. Polypharmacy and inappropriate medication use in patients with dementia: an underresearched problem. Therapeutic Adv drug Saf. 2017;8(1):31–46. doi: 10.1177/2042098616670798.
Downloads
How to Cite
Issue
Section
License
Copyright (c) 2025 Atef Eid Madkour Elsayed, Omar Ahmad Saleh Alzahrani, Rakan Al-Anzi, Nwaf Khalid Alsulimani, Omar Zaid Alharbi, Abdullah Olayan Alrasheed, Nisrin Hassan Kharezi, Abdullah Mohammed Alshehri, Ali Abdullah Al-Nasser, Zahra Saeed Yusuf, Mishaal Mansour Al Saud

This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their published articles online (e.g., in institutional repositories or on their website, social networks like ResearchGate or Academia), as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
Except where otherwise noted, the content on this site is licensed under a Creative Commons Attribution 4.0 International License.